A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This randomized, parallel arm study will evaluate the efficacy and safety of Pegasys
(peginterferon alfa-2a) in combination with 2 different doses of ribavirin in patients with
chronic hepatitis C, genotype 2 or 3. Patients will be randomized to 4 treatment groups
receiving Pegasys (180 mcg subcutaneously weekly) for either 16 or 24 weeks with one of two
doses of ribavirin (400 mg or 800 mg orally daily). The anticipated time on study treatment
is 16 or 24 weeks with a 24-week follow-up.